Cabaletta Bio (CABA) said Monday it priced an underwritten offering of 51.7 million shares at $2.90 apiece, raising $150 million in gross proceeds.
The drugmaker said proceeds from the offering, expected to close Tuesday, will support development of its lead candidate rese-cel and broader clinical pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.